Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Freenome is conducting the PREEMPT CRC study, a >35,000-person prospective study for colorectal cancer (CRC) evaluating Freenome's blood-based screening test for CRC in the average-risk population.

Older Freenome data suggest its test in early-stage colorectal cancer has 94% sensitivity — the ability to show who truly has cancer — and a specificity of 94%, meaning 6% of tests result in ...

Freenome said the money would be used for a validation study and would then submit an application for its colorectal cancer screening test to both the U.S. Food and Drug Administration (FDA) and ...

Freenome has leased two buildings at a 438,000-square-foot biotech complex at in Brisbane.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine ...

Freenome Holdings Inc. has raised $270 million to pursue U.S. regulatory approval of a blood test to detect colorectal cancer, part of a push by molecular-testing companies to enable earlier ...